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Abstract
Background: The current study was undertaken to determine the degree of activation of gallbladder mucosal
mast cells, whether mast cell (MC) density or activation differ between patients with and without a positive clinical
response to cholecystectomy, and whether either density or activation correlate with gallbladder emptying.
Results: Fifteen biliary dyskinesia (BD) and 13 symptomatic cholelithiasis (CL) patients undergoing cholecystectomy
were prospectively enrolled. Gallbladder wall MC density (by immunohistochemistry) and activation (by electron
microscopy) were determined. Clinical response was evaluated 30 days post-cholecystectomy on a 5-point Likert-
type scale. A complete or nearly complete clinical response was seen in 100% of CL and in 87% of BD patients.
The overall degranulation indices were 49.4 ± 18.7% for CL patients and 44.2 ± 16.8% for BD patients. Neither MC
density nor activation correlated with the gallbladder ejection fraction. A complete clinical response was associated
with lower epithelial MC density.
Conclusion: Cholecystectomy is efficacious in relieving pain in both CL and BD patients. BD and CL are associated
not only with increased MC density but a moderate to high degree of MC activation. A possible relationship
between MC density and outcome for BD warrants further investigation.
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Background
The Rome III working group defined a number of func-
tional gastrointestinal disorders in adults and children
[1,2]. Functional gallbladder disorder (FGD), previously
known as biliary dysfunction) was included in the adult
but not the pediatric diagnoses. FGD is defined by
recurrent symptoms of pain in the epigastrium or right
upper quadrant lasting 30 minutes or longer and occur-
ring at different intervals, among other criteria [3]. Sup-
port for this diagnosis is provided by an abnormal
gallbladder ejection fraction with a normal hepatobiliary
ultrasound and laboratories [3]. For children, the entity
which would most closely resemble FGD has been
termed biliary dyskinesia. Biliary dyskinesia (BD) and
cholelithiasis (CL) are the most common indications for
cholecystectomy in children and adolescents [4-6].
Although there has been extensive evaluation of the
pathophysiology of cholelithiasis, the pathophysiology of
FGD or BD has not been well described. Previously we
evaluated gallbladder wall inflammatory cells in children
with symptomatic CL and BD [7]. These two conditions
were associated with a 9 to 12-fold increase in mucosal
MC density. This parallels other functional gastrointest-
inal disorders, specifically functional dyspepsia and irri-
table bowel syndrome, which have been associated with
increased MCs in the stomach, small bowel, and/or
large bowel [8-11].
While we have previously demonstrated increased MC
density in BD and symptomatic CL, this is not sufficient
alone to implicate MCs in the pathogenesis or genera-
tion of symptoms in these patients. A large part of the
biologic activity of MCs is attributable to released med-
iators which are active in a concentration-dependent
fashion [12]. Thus, the biologic activity of MCs is
defined not only by density but by the degree and loca-
tion of activation. This distinction can be demonstrated
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of IBS in adults. IBS has been associated with increased
MCs in the terminal ileum, cecum, proximal descending
colon, and rectum [9-11,13]. IBS patients also demon-
strate increased density of activated or degranulating
MCs as compared to controls and in IBS patients, MCs
in close proximity to nerves are more likely to be acti-
vated [11,13]. Only the MC density in close proximity
to nerves is correlated with the severity and frequency
of pain in these patients [11].
If MCs are to be implicated in the pathogenesis of BD
or symptomatic CL, not only do MCs need to be
increased in density but it needs to be demonstrated
that MCs are actively releasing mediators. The current
study was undertaken to assess the degree of gallbladder
mucosal MC activation. In addition, this study evaluated
whether MC density or activation differ between
patients with and without a positive clinical response to
cholecystectomy.
Methods
This was a prospective study evaluating gallbladder his-
tology (specifically MC density and activation) and post-
operative clinical response in patients undergoing
laparoscopic cholecystectomy between February, 2006
and September, 2008 for symptomatic CL and BD. The
study was approved by the Institutional Review Board at
Children’s Mercy Hospital in Kansas City and written
consent/assent was obtained for all participants prior to
participation in the study.
Patient Selection
Patients were eligible for enrollment if they had right
upper quadrant (RUQ) or epigastric pain of at least 8
w e e k sd u r a t i o nf r o mt h eo n s e to ft h ef i r s tb o u ta n d
were scheduled for cholecystectomy. BD patients were
required to demonstrate delayed gallbladder emptying
(EF < 35%) following CCK stimulation on a single cho-
lescintigraphy. Reproduction of pain during cholescinti-
graphy was not considered. CL patients were required
to have the presence of a gallstone within the gallblad-
der on ultrasound.
Patients were not excluded for pain in other regions in
addition to the RUQ or epigastric pain. Patients were
excluded from either group for evidence of biliary
obstruction defined as direct bilirubin ≥ 1.0 mg/dL on
any previous laboratory evaluations or common bile
duct diameter ≥ 7 mm on any previous ultrasound.
Patients were excluded if they had received anti-inflam-
matory medications or had a history of inflammatory
bowel disease, rheumatologic disease, or cancer. In addi-
tion, BD patients were required to exhibit normal filling
(< 1 hour)on cholescintigraphy.
Histology
Sections from the body of the resected gallbladders were
embedded and processed in the usual fashion including
staining with hematoxylin and eosin for the usual evalua-
tion by a board certified pediatric pathologist. Additional
specimens were obtained for immunohistochemical (IHC)
staining for MCs. For IHC evaluation, serial 3- μm paraf-
fin sections were air dried and fixed on slides. The sec-
tions were deparraffinized using a xylene substitute and
then rehydrated in alcohol to tris-buffered saline. Endo-
genous peroxidase activity was blocked using 3% hydro-
gen peroxide followed by a protein block with 5% goat
serum. Residual biotin and avidin activity were quenched
using avidin and biotin block, respectively. Monoclonal
mouse anti-human mast cell tryptase, Clone AA1 was
used as the primary antibody and applied as a 1:1000
dilution for 1 hour at room temperature (18°C - 25°C).
Labeled streptavidin-biotin (LSAB) was used for the
detection system with diaminobenzidine tetrahydrochlor-
ide (DAB) as the chromogen. Sections were counter-
stained with hematoxylin. MCs were enumerated for 10
high power fields per layer (epithelium, lamina propria,
and muscularis mucosae) by a single investigator (NN).
The largest MC count in any 40X high power field (hpf)
was reported as the peak and the average number/hpf
was reported as the mean.
Electron Microscopy
Specimens for electron microscopic (EM) evaluation
were obtained in the operating room immediately fol-
lowing cholecystectomy and were placed in 2% glutaral-
dehyde in 0.1 M sodium cacodylate, pH 7.4. All
specimens were taken from the body of the gallbladder
and were approximately 5 mm × 5 mm. Specimens were
post fixed in osmium tetroxide. The tissue was then
dehydrated in graded alcohols and embedded in epoxy
resin. Sections were cut at 80 nm thickness and con-
trasted with uranyl citrate and lead citrate. Transmitting
EM was performed and MCs were identified and photo-
graphed at 4800X. The photographs were then evaluated
and the MC degranulation index was calculated by pre-
viously described methodology [14]. The number of
granules exhibiting loss of density or vacuolization was
divided by the total number of granules. Degranulation
indices were not evaluated by layer as the layers could
not be precisely distinguished on EM.
Clinical Outcome
A standardized history regarding the patient’ss y m p -
toms was obtained pre-operatively and 30 days follow-
ing cholecystectomy. The follow-up evaluation also
included an assessment of the patient’s global clinical
response utilizing a Likert-type scale adapted to assess
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relief grades were:
Grade 1 Worse- clinical deterioration with increas-
ing pain intensity and/or frequency.
Grade 2 No change- no increase or decrease in pain
intensity or frequency
Grade 3 Moderate improvement- partial clinical
response with definite improvement in pain, but not
meeting the criteria for a Grade 4 response
Grade 4 Good- nearly complete relief of symptoms
with minimal residual pain and pain not interfering
with daily activities
Grade 5 Excellent- complete relief of pain
Statistics
The frequencies for individual symptoms were com-
pared between the pre- and post-cholecystectomy time
points by chi square analysis or the Fisher’se x a c tt e s t .
The percentage of patients with elevated peak and mean
cell densities, respectively, was determined. The upper
limit of normal was determined as the mean + 2 SD
from previous control data with upper limits defined as
mean > 3.5/hpf in the LP, peak > 5.78/hpf in the LP,
mean > 1.66/hpf in the MM, and peak > 4.19 in the
MM [7]. MC densities were compared between BD and
CL patients by the student’s t test. MC densities were
compared between patients with and without chronic
cholecystitis for all patients and for BD patients only by
the student’s t test. Pearson correlation coefficients were
determined for the gallbladder ejection fractions with
the MC densities and MC degranulation indices, respec-
tively. Pearson correlation coefficients were determined
for length of symptoms with the MC densities and MC
degranulation indices, respectively. Mucosal MC densi-
ties were compared by layer between patients with a
complete clinical response (grade 5) and lesser respon-
ders by ANOVA. A p value < .05 was considered
significant.
Results
Fifteen patients with BD and 13 symptomatic patients
with CL who were scheduled for cholecystectomy were
prospectively enrolled in this study. BD patients ranged
in age from 8 to 17 years (mean 13.3 ± 2.7 years). Most
were female (87%) and Caucasian (93%). CL patients
ranged in age from 6 to 18 years (mean 12.2 ± 3.0
years). Again, most (85%) were female, 77% were Cauca-
sian, 15% were African-American, and 8% were Hispa-
nic. The presenting symptoms are shown in Table 1.
For patients with BD, 66.7% had pain only in the right
upper quadrant (RUQ), 6.7% only in the epigastrium,
and 6.7% in both the RUQ and epigastrium. For CL
patients, 69.2% had pain only in the RUQ, 15.4% only in
the epigastrium, and 7.7% in both the RUQ and epigas-
trium. The remaining patients also had pain in other
areas of the abdomen.
The percentage of patients exhibiting a particular
symptom at 30 days post-cholecystectomy is also shown
in Table 1. One CL patient was lost to follow-up. There
was a significant decrease in the frequency of pain, pain
with eating, night time waking with pain, and nausea,
respectively, in both patient groups. There was a signifi-
cant decrease in vomiting frequency in the CL patients
only. The global response grades are shown in Figure 1.
Ninety- two percent of CL patients achieved a grade 4
or 5 response. Ninety-three percent of BD patients had
a positive clinical response with 87% achieving a grade 4
or 5 response.
Table 1 The percentage of patients exhibiting particular
symptoms preoperatively and 30 days post-
cholecystectomy
Cholelithiasis Biliary Dyskinesia
Symptom Pre Post p
value
Pre Post p
value
Pain 100% 15.4% < .01 100% 20% < .01
Pain with eating 61.5% 15.4% < .01 80% 6.7% .04
Night waking with pain 84.6% 7.7% .02 60% 6.7% < .01
Nausea 100% 15.4% < .01 80% 20% < .01
Vomiting 53.8% 7.7% < .01 40% 6.7% .03
Diarrhea 23.1% 7.7% .17 33.3% 6.7% .17
Constipation 30.8% 46.2% .40 20% 20% 1.00
Pain decreased with
stool
7.7% 7.7% 1.00 26.7% 20% 1.00
Figure 1 Global clinical response grades for biliary dyskinesia
(BD) and cholelithiasis (CL) patients 30 days post-
cholecystectomy.
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Chronic cholecystitis as determined by the pathologist
was present in 85% of BD patients and 53% of CL
patients. Pigmented stones were identified in 46.2% and
cholesterol stones in 53.8% of the CL patients. The MC
densities by layer are shown for both patient groups in
Table 2. A representative IHC anti-tryptase stained spe-
cimen is shown in Figure 2. For CL patients, the means
and peaks were elevated in all patients in both the LP
and the MM. For BD patients, means were elevated in
all patients in both the LP and MM and peaks were ele-
vated in all patients in the LP and all but one patient in
the MM. There was no significant correlation between
the MC density and the ejection fraction. Both mean
and peak epithelial MC densities were lower in complete
responders (grade 5, N = 12) as compared to lesser
responders (grades 2-4, N = 3) in BD patients. (Figure
3) There was no overlap in values between the 2 groups.
The mean values in lesser responders ranged from 0.4
to 1.2/hpf while all complete responders had values ran-
ging from 0 to 0.3/hpf. The peak values in lesser respon-
ders ranged from 2 to 4/hpf while complete responders
had values ranging from 0 to 1/hpf. There were no dif-
ferences in mast cell density in either the LP or the
MM. There was no difference in density between pig-
mented and cholesterol stone patients. There were no
differences in densities between patients with and with-
out chronic cholecystitis for all patients combined or for
BD patients only. For CL patients only, muscularis
mucosae mean (r = 0.700, p = .017) and peak (r =
0 . 7 2 4 ,p=. 0 1 2 )M Cd e n s i t i e sc o r r e l a t e dw i t hl e n g t ho f
symptoms.
Mast Cell Degranulation
A mean of 5.8 cells per patient (range 1-22) were evalu-
ated. All but two patients had 3 or more cells evaluated.
A mean of 458 granules per patient (range 71-1814)
were evaluated. There was no correlation between the
number of granules evaluated and the degranulation
index (r = .000, p = .999). The overall MC degranulation
indices were 49.4 ± 18.7% for the CL patients and 44.2
± 16.8% for the BD patients. The comparative distribu-
tion of indices is shown in Figure 4. Overall,
degranulation indices between 25 and 75% were seen in
77% of CL patients and 73% of BD patients. Representa-
tive electron micrographs of MCs are shown in Figures
5, 6, 7, and 8. Most MCs demonstrated piecemeal degra-
nulation with variable numbers of partially and comple-
tely empty granules [15].
There was no significant correlation between MC
degranulation and the ejection fraction. In BD patients
only, there was a significant correlation between degra-
nulation indices and both the mean (r = .534, p < .05)
and peak (r = .632, p = .015) MC densities in the lamina
propria. There were no differences between complete
responders and lesser responders. Degranulation indices
did not correlate with the length of symptoms in either
CL or BD patients.
Table 2 Mast cell densities by layer for cholelithiasis and
biliary dyskinesia patients
Layer Cholelithiasis Biliary Dyskinesia p value
Epithelium mean .36 ± .33 .25 ± .37 .43
peak 1.18 ± .75 1.07 ± 1.20 .79
Lamina propria mean 17.01 ± 7.92 11.90 ± 2.90 .035
peak 24.55 ± 9.49 18.57 ± 4.69 .05
Muscularis mean 11.33 ± 6.76 9.64 ± 3.94 .33
Mucosae peak 17.91 ± 10.52 14.71 ± 5.25 .68
Figure 2 Representative anti-tryptase stain in a patient with
biliary dyskinesia. (400X).
Figure 3 Mean and peak epithelial mast cell densities in BD
patients with a complete clinical response to cholecystectomy
as compared to those with a partial response or non-
responders.
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We have previously found that BD and symptomatic CL
are associated with a 9- to 12-fold increase in gallblad-
der wall MCs when compared to controls [7]. In the
current study, we confirmed that MCs are frequently
present in the gallbladder wall at counts very similar to
what was observed in our previous study. MCs have
been implicated in other functional gastrointestinal dis-
orders. Increased gastric MCs have been reported in
adults with functional dyspepsia [8]. Increased MCs
have been found in the ileum and colon of adults with
irritable bowel syndrome [9-11]. Similar to our previous
report, MC density was increased in the lamina propria
and the muscularis mucosae in both CL and BD
patients. For CL patients, this is similar to findings pre-
viously reported in adults with CL which demonstrated
increased MC density and % of degranulated MCs in
the muscular layer of adults with gallstones as compared
to controls [16]. Unlike our previous report, MCs in the
l a m i n ap r o p r i aw e r es i g n i f i c a n t l yi n c r e a s e di np a t i e n t s
with CL as compared to patients with BD. The signifi-
cance of this finding is not known. Moreover, it is possi-
ble that this represents a reaction to the stone itself or
to an abnormal bile acid pool which may be present in
stone formers. As we only studied symptomatic CL
patients, it is not known whether MCs are unique to
patients experiencing pain or whether they are also
found in asymptomatic patients.
While we diagnosed BD in the current study utilizing
adult criteria for functional gallbladder disorder, it
should be noted that 85% of the patients in this group
demonstrated chronic cholecystitis on pathologic exami-
nation. Our findings are consistent with other reports of
Figure 4 Distribution of mast cell degranulation indices for
biliary dyskinesia (BD) and cholelithiasis (CL) patients.
Figure 5 Electron micrograph of a normal intact mast cell with
homogenous electron-dense granules.
Figure 6 Electron micrographs of mast cells demonstrating
varying degrees of piecemeal degranulation evidenced by
partially and completely empty granule chambers.
Figure 7 Electron micrographs of mast cells demonstrating
varying degrees of piecemeal degranulation evidenced by
partially and completely empty granule chambers.
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cholecystitis has been reported in 44-93% of patients
[6,17,18]. This raises the question of whether these
patients should be diagnosed with acalculous cholecysti-
tis or whether chronic inflammation contributes to the
pathogenesis or functional gallbladder disorders. This
w o u l db ea n a l o g o u st ot h ei n c r e a s ei nc o l o n i cl y m p h o -
cytes reported in post-infectious irritable bowel syn-
drome [19]. Whether chronic inflammation is important
in symptom generation is also unclear. In two previous
studies, the proportion of patients with chronic chole-
cystitis did not differ between patients experiencing
positive benefit from cholecystectomy as compared to
those who did not [17,18].
A major focus of the current study was to define the
degree of activation of gallbladder wall MCs by elec-
tron microscopy. The primary biologic and pathophy-
siologic actions of MCs result from the release of
specific mediators which are often active in a concen-
tration-dependent fashion. Thus the activity of MCs is
defined by the density and degree of activation and
degranulation [12]. Although there are no established
norms for intestinal mast cell degranulation indices in
the gastrointestinal tract, we have demonstrated a
moderate to high degree of activation comparable to
that seen in other diseases where MCs are known to
h a v eap a t h o p h y s i o l o g i cr o l e[ 1 4 ] .M Cp r o d u c t sh a v e
the potential to result in pain through direct stimula-
tion of sensory nerves or induction of visceral hyperal-
gesia. MC activation has been associated with pain
severity and increased visceral sensitivity in adults with
both functional dyspepsia and irritable bowel syndrome
[11,14,20]. MC degranulation results in a decreased
threshold for the pain response with balloon distension
and this hyperalgesic response can be prevented with
MC-stabilizing medication [21] MC may also create
gallbladder symptoms through the generation of gall-
bladder spasm. Two MC products, histamine and leu-
kotrienes, have been shown to increase the excitability
of gallbladder smooth muscle and lead to contraction
[22-25]. We were unable to demonstrate a correlation
between MC density or activation and the ejection
fraction although this may be the result of the sensitiv-
ity of the method employed. The activation index is a
general indicator of activation but may be limited in
assessing specific pathophysiologic processes. MCs pro-
duce many mediators which may be selectively released
with varying physiologic actions. Additionally, while
EM activation has been described in conditions where
MCs appear to play a role, there is no “gold standard”
measure of MC activation which would allow assess-
ment of the accuracy of degranulation indices. Further
work is necessary to determine if specific mediators
are responsible for the observed dysmotility.
Another focus of the current study was to prospectively
evaluate global response, to determine which symptoms
improve with cholecystectomy, and to evaluate whether
there is a relationship between MC density or activation
and clinical response. Consistent with previous reports, a
complete or nearly complete clinical response was seen
in all CL patients. Specific symptoms decreasing in fre-
quency were abdominal pain, pain with eating, night wak-
ing with pain, nausea, and vomiting while lower tract
symptoms (diarrhea, constipation, and pain improving
with a stool) did not improve. Cholecystectomy resulted
in a complete clinical response in 80% of BD patients,
with an additional 15% experiencing clinical improve-
ment. Specific symptoms decreasing in frequency were
abdominal pain, pain with eating, night waking with pain,
and nausea. Again, lower tract symptoms did not
decrease in frequency postoperatively. Our response rate
for BD is consistent with previous studies, most of which
have been retrospective. As reviewed by Constantinou, et
al, eleven previous studies reported postoperative
response rates varying from 71-100% [17]. Constantinou,
et al, also reported outcomes following cholecystectomy
in 100 children with BD where outcome data were col-
lected prospectively [17]. Similar to our patients, 77%
reported resolution of symptoms at 6 months to 5 years
postoperatively. The only randomized trial for BD was
performed in adults [26] This study found cholecystect-
omy to be more efficacious than observation. Siddiqui, et
al, retrospectively evaluated the degree of response to
cholecystectomy for BD in children [27]. Similar to our
patients, the overall response rate was 93% with 65%
reporting resolution of symptoms and 28% reporting
improvement with some residual symptoms. Overall, our
study adds to the previous prospective study and con-
firms the clinical efficacy that has been reported in the
previously cited retrospective studies.
Figure 8 Electron micrograph of a mast cell demonstrating
nearly complete degranulation.
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and the clinical response grade for either patient group
was demonstrated in the BD patients. A complete clinical
response was associated with lower epithelial MC density
when compared to a partial or non-response. The reason
for this is not clear. It is possible that higher MC density
may be associated with MCs in the gastrointestinal tract
resulting in dyspepsia or irritable bowel syndrome. This
could not be evaluated in the current study as only a few
patients underwent endoscopic evaluation. There are
insufficient data to determine whether there is clinical
value to obtaining gastrointestinal biopsies prior to chole-
cystectomy. These data (both the positive findings in the
epithelium and the negative findings in other layers) need
to be interpreted with caution as there were so few par-
tial or non-responders for comparison. The positive find-
ings may simply represent a type II statistical error.
Larger studies are necessary to evaluate the relationship
between MCs and outcome.
Conclusions
In the current study, we have demonstrated a moderate
to high degree of mast cell activation in BD and CL
which along with the previously demonstrated high MC
density (confirmed in the current study) suggests a pos-
sible role for MCs in the pathophysiology of these con-
ditions. Future work evaluating concentrations of
gallbladder wall mediators such as proteases or cyto-
k i n e si sn e c e s s a r yt of u r t h e r delineate possible patho-
physiologic mechanisms. We have demonstrated a
relationship between MC density and outcome for bili-
ary dyskinesia which also warrants further investigation.
A better understanding of the pathophysiology may lead
to better identification of patients who will have clinical
benefit from cholecystectomy or who might respond to
medications such as mast cell stabilizers.
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